scholarly journals Resistance to ceftazidime/avibactam in infections and colonizations by KPC-producing Enterobacterales: a systematic review of observational clinical studies

Author(s):  
Stefano Di Bella ◽  
Daniele Roberto Giacobbe ◽  
Alberto Enrico Maraolo ◽  
Valentina Viaggi ◽  
Roberto Luzzati ◽  
...  
2021 ◽  
pp. 174248
Author(s):  
Kiarash Saleki ◽  
Shakila Yaribash ◽  
Mohammad Banazadeh ◽  
Ehsan Hajihosseinlou ◽  
Mahdi Gouravani ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 351
Author(s):  
Massimiliano Creta ◽  
Giuseppe Celentano ◽  
Luigi Napolitano ◽  
Roberto La Rocca ◽  
Marco Capece ◽  
...  

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.


Gene Reports ◽  
2021 ◽  
pp. 101265
Author(s):  
Fereshteh Hasanpour ◽  
Zohreh Neyestani ◽  
Mohsen Arzanlou ◽  
Eslam Moradi-Asl ◽  
Amirhossein Sahebkar ◽  
...  

Author(s):  
Sarah E. Steane ◽  
Sophia L. Young ◽  
Vicki L. Clifton ◽  
Linda A. Gallo ◽  
Lisa K. Akison ◽  
...  

2022 ◽  
Vol 104-B (1) ◽  
pp. 12-18
Author(s):  
Simon Weil ◽  
Magnus Arnander ◽  
Yemi Pearse ◽  
Duncan Tennent

Aims The amount of glenoid bone loss is an important factor in deciding between soft-tissue and bony reconstruction when managing anterior shoulder instability. Accurate and reproducible measurement of glenoid bone loss is therefore vital in evaluation of shoulder instability and recommending specific treatment. The aim of this systematic review is to identify the range methods and measurement techniques employed in clinical studies treating glenoid bone loss. Methods A systematic review of the PubMed, MEDLINE, and Embase databases was undertaken to cover a ten-year period from February 2011 to February 2021. We identified clinical studies that incorporated bone loss assessment in the methodology as part of the decision-making in the management of patients with anterior shoulder instability. The Preferred Reporting Items for Systematic Reviews (PRISMA) were used. Results A total of 5,430 articles were identified from the initial search, of which 82 studies met the final inclusion criteria. A variety of imaging methods were used: three studies did not specify which modality was used, and a further 13 used CT or MRI interchangeably. There was considerable heterogeneity among the studies that specified the technique used to quantify glenoid bone loss. A large proportion of the studies did not specify the technique used. Conclusion This systematic review has identified significant heterogeneity in both the imaging modality and method used to measure glenoid bone loss. The recommendation is that as a minimum for publication, authors should be required to reference the specific measurement technique used. Without this simple standardization, it is impossible to determine whether any published paper should influence clinical practice or should be dismissed. Cite this article: Bone Joint J 2022;104-B(1):12–18.


Sign in / Sign up

Export Citation Format

Share Document